sur BioNxt Solutions Inc. (CVE:BNXT)
BioNxt Progresses in Semaglutide Oral Dissolvable Film Development
BioNxt Solutions Inc. announced a step forward in its Semaglutide oral dissolvable film (ODF) program into active pharmaceutical development. This initiative is in collaboration with Gen-Plus GmbH, a German drug developer. The move highlights BioNxt’s strategic milestone as it enters the GLP-1 therapeutics market. This market is swiftly expanding globally, focusing on obesity, metabolic disorders, and type 2 diabetes.
Semaglutide, the main ingredient in many GLP-1 therapies, benefits from BioNxt's expertise in sublingual thin-film drug delivery systems. The new development aims to offer a needle-free, patient-friendly treatment option, enhancing convenience and adherence for patients managing chronic diseases.
The initial phase of development will span six to nine months. Key activities include formulation development, testing of components, and proof-of-concept evaluations. Outcomes from these studies could lead to the next steps in formulation optimization and scaling up the process.
R. E.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de BioNxt Solutions Inc.